GEXVal to Host Australian Clinical Development Seminar at BioJapan 2025

株式會社GEXVal
October 2, 2025

GEXVal to Host Seminar on Value Creating Early Clinical Development in Australia at BioJapan 2025 in Yokohama

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that it will host a panel discussion at BioJapan 2025.

[Event Overview]
Australia has emerged as a strategic destination for early-stage clinical development. For this seminar, GEXVal has brought together leading Australian CDMO, Phase I unit, and clinical development CRO—key players in the country's clinical development ecosystem—to share practical insights and lessons learned through panel discussions based on GEXVal's Phase I clinical trial experience in Australia.

GEXVal will also be exhibiting in Hall D during BioJapan 2025.

**Presentation Details**

[CEO Statement]
President and CEO Dr. Juran Kato commented: "We are thrilled to share the real-world experience and know-how we gained navigating our Phase I trial in Australia. Working with leading local players, we'll dive into specific cases and practical challenges to give Japan's drug discovery community more strategic options. We aim to share our experience and contribute to Japanese biopharmas accelerating their global development more efficiently. This is just one example of how we're working with partners worldwide to push the boundaries of what's possible in medicine."

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com